Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: drdan who wrote (1949)	6/27/1998 6:15:00 PM
From: Mr. Forthright	Read Replies (4) \| Respond to of 5402

drdan, I agree that big pharma will sign deals with biotech companies prior to approval. What I am trying to do is point out to investors the fact that SGNC may have a chance to succeed where so many others have failed but that is several years away. Valuation of biotech companies is driven by the size of the potential market and events that lead to a reduction of risk such as financings, clinical trials results and/or deals with big pharmas. SGNC is going after a potentially very large market but there is considerable risk involved still. Anybody that is trying to hype the stock or make investors believe that the reward will come soon is either a total biotech neophyte or is simply misleading people. I don't think you are a total neophyte nor that you are trying to mislead investors. I think you are just a little bit too enthusiastic at this stage.